Gsk (GSK) Price to FCF (2026)

Gsk (GSK) has 18 years of Price to FCF data on file, last reported at 6.39 in Q3 2026.

• For the quarter ending Q3 2026, Price to FCF changed N/A year-over-year to 6.39; the trailing twelve-month figure through Sep 2026 stood at 6.39 (changed N/A YoY), and the FY2025 full-year result was 8.75, up 21.96% from the prior year.
• Price to FCF was 6.39 for Q3 2026 at Gsk, down from 7.87 in the prior quarter.
• In the past five years, Price to FCF ranged from a high of 10.2 in Q1 2024 to a low of 4.78 in Q3 2022.
• A 5-year average of 7.85 and a median of 8.02 in 2023 frame the typical range for Price to FCF.
• Across the five-year window, Price to FCF surged 63.97% in 2023 and retreated 29.52% in 2024, its largest moves.
• Gsk's Price to FCF stood at 6.19 in 2022, then soared by 63.97% to 10.14 in 2023, then retreated by 29.52% to 7.15 in 2024, then climbed by 17.02% to 8.36 in 2025, then slipped by 23.56% to 6.39 in 2026.
• Per Business Quant data, the three most recent Price to FCF figures were 6.39 in Q3 2026, 7.87 in Q2 2026, and 9.32 in Q1 2026.